We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Sign up to read this article for FREE!

After signing up, you'll start to receive regular news updates from us.

Sigma-Aldrich Introduces Mission® Lentiplex™ Pooled shRNA Libraries

Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute
Sigma-Aldrich has announced the global release of the MISSION® LentiPlex™ Pooled Human and Murine shRNA Libraries.

Using the shRNA collections of The RNAi Consortium (TRC), the MISSION LentiPlex Pooled shRNA Libraries enable genome-wide RNAi screening at the bench-top level in a powerful, pooled lentiviral format. As a member of both TRC-1 and TRC-2 collaborations, Sigma-Aldrich is the exclusive commercial source for access to TRC shRNA libraries in lentiviral format.

The MISSION LentiPlex Pooled shRNA Libraries were developed from the entire TRC-1 human and mouse collections of more than 158,000 shRNA constructs targeting approximately 16,000 human genes and approximately 16,000 mouse genes.

Combining Sigma-Aldrich’s high-throughput lentiviral production methodologies with the pooled library format enables researchers to perform genome-wide RNAi screens on various cell types, discovering new targets without a large investment in infrastructure.

LentiPlex enables researchers to screen for novel phenotypes in relevant cell lines and study gene function and disease, both in standard cell lines and difficult cell types such as primary, non-dividing, growth-arrested or terminally differentiated cells that are typically resistant to standard siRNA transfection or other viral delivery systems.

In addition, Sigma-Aldrich’s shRNA libraries include a U6 promoter for shRNA expression in a wide variety of cell lines including embryonic stem cells. These characteristics mean researchers can now conduct high quality pooled shRNA screens in the cell lines of their choice.